Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
- MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024.
- 06/05/2024
|
Immuron Board Changes
- MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today.
- 05/31/2024
|
Immuron CEO Steven Lydeamore to present at Peak Sky High
- MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024.
- 05/31/2024
|
Immuron Limited to Present at the Emerging Growth Conference
- MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May.
- 05/07/2024
|
Immuron Director Resignation
- MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests.
- 05/03/2024
|
Immuron to host Live Virtual Event
- MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT.
- 04/15/2024
|
Immuron Travelan® sales continued strong growth
- Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcp Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcp Mar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarter Sales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Sales of Travelan® increased 250% to AUD $2.7 million FYTD Mar 2024 compared to AUD $0.8 million FYTD Mar 2023.
- 04/10/2024
|
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
- Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint) 66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secondary endpoint) 83.3% statistically significant reduction in the number of subjects in the Travelan® group requiring early antibiotic treatment post challenge compared to the placebo (secondary endpoint) 100% of the subjects requiring IV fluids post challenge were in the placebo (secondary endpoint) 55.6% reduction in the number of subjects experiencing adverse events associated with the ETEC challenge observed in the Travelan® group compared to the placebo group (secondary endpoint) Phase 2 clinical study data supports the excellent safety and tolerability profile of Travelan® MELBOURNE, Australia, March 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli (ETEC). Immuron was awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense (ASX Announcement 12 January 2022) to perform a randomized double-blind placebo-controlled phase 2 controlled human infection model (CHIM) study to assist with evaluating a dosing regimen that is most suited to deployed US troops visiting developing countries.
- 03/07/2024
|
Immuron Presentation Australian Biologics Festival 2024
- MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.
- 02/21/2024
|
Immuron achieves record Travelan® sales
- Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan® YTD Jan 2024 sales $2.1 million USA Travelan® YTD Jan 2024 sales $0.6 million Canadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Australia Sales of Travelan® increased to AUD $2.1 million YTD Jan 2024 compared to AUD $0.3 million YTD Jan 2023.
- 02/13/2024
|
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
- MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia.
- 02/08/2024
|
Immuron achieves record half yearly Travelan® sales
- Highlights: Record half yearly Travelan® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Australia Sales of Travelan® increased to AUD $1,853,048 in H1, FY24, compared to AUD $260,205 in H1, FY23.
- 01/16/2024
|
Immuron Clinical Trials Update
- Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completed Pre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company's clinical development portfolio. The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
- 12/22/2023
|
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
- Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis New CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers' diarrhea The in-patient stage of the study is anticipated to be completed by the end of December 2023 MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
- 12/04/2023
|
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
- MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST.
- 11/28/2023
|
Immuron CEO Steven Lydeamore Investor Webinar Presentation
- MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.
- 11/13/2023
|
Immuron CEO Steven Lydeamore presented at AusBioInvest
- MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.
- 10/30/2023
|
Immuron Announces Travelan® Clinical Study Cohort 2 commences
- Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohort The clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024 Travelan® is known to protect against the onset of Traveler's diarrhea (TD), the most common illness reported by travelers MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC). The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
- 10/18/2023
|
Immuron achieves record quarterly Travelan® sales
- Highlights: Record quarterly Travelan® sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales 130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®. Australia Immuron previously reported (August 9, 2023) that short term stock outages of Travelan® in some wholesalers and pharmacies in the June 2023 quarter was resolved following receipt of GMP Clearance from the Therapeutic Goods Administration (TGA).
- 10/11/2023
|
Immuron Limited Announces Participation in the LD Micro Main Event XVI
- Presentation on Wednesday, October 4th at 11:00 PT Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announced today that it will be presenting at the 16th annual Main Event on Wednesday, October 4th at 11:00 PT at the Luxe Sunset Boulevard Hotel. Steven Lydeamore, CEO, will be giving the presentation.
- 09/18/2023
|
Immuron achieves record monthly Travelan® sales
- Highlights: Record monthly Travelan® sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
- 09/13/2023
|
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
- MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th.
- 09/11/2023
|
Immuron to present at the Military Health System Research Symposium
- MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium (MHSRS), in Kissimmee, Florida from the 14th to the 17th of August 2023.
- 08/14/2023
|
Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment
- The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmaceutical company said the U.S. Food and Administration has removed a clinical hold on the Investigational New Drug (IND) application for its diarrhea treatment.
- 05/08/2023
|
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
- MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore.
- 05/02/2023
|
Immuron CEO highlights strong sales growth in business update presentation
- Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore highlighted the strong growth in sales of oral immunotherapeutic products in the company's February 2023 business update presentation for investors. Lydeamore noted that the company posted revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.
- 03/06/2023
|
The Top Indicators That Penny Stocks Traders Use
- Use these indicators for buying penny stocks in 2022 The post The Top Indicators That Penny Stocks Traders Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/25/2022
|
Immuron CEO, Steven Lydeamore to present at AusBioInvest
- MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore.
- 10/26/2022
|
Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript
- Immuron Limited (NASDAQ:IMRN ) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive Officer Conference Call Participants Unidentified Company Representative Good morning, everyone. And welcome to Immuron's Full Year Results Webinar.
- 09/06/2022
|
Best High Volume Penny Stocks to Watch Right Now
- Check these three penny stocks out for your watchlist right now The post Best High Volume Penny Stocks to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/18/2022
|
IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?
- Today marks one of the best days for IMRN stock in a long time, with shares surging nearly 50% on the back of some impressive news. The post IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?
- 01/12/2022
|
Here is why Immuron is up 30% on Wednesday
- Immuron Limited (NASDAQ: IMRN) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan. This new research agreement with the DoD aims to confirm and test the efficacy of dosing regimens of Travelan in a CHIM (controlled human infection […] The post Here is why Immuron is up 30% on Wednesday appeared first on Invezz.
- 01/12/2022
|
Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M
- Immuron Limited (NASDAQ: IMRN) has received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military. The Company has received A$4.8 million funding from the U.S. Department of Defense for Travelan and A$1.4 million from the U.S Naval Medical Research Center to support the Travelan clinical development effort.
- 01/12/2022
|
Immuron Stock (IMRN): Why The Price Surged Today
- The stock price of Immuron (NASDAQ: IMRN) increased by over 80% pre-market today. This is why it happened.
- 01/12/2022
|
Immuron stock rockets after funding by U.S. DoD of new research agreement
- Shares of Immuron Ltd. IMRN, +2.67% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use.
- 01/12/2022
|
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
- Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel.
- 10/08/2021
|
IMM-124E – Demonstrates Antiviral T-Cell Immunity
|
Immuron Director resignation
- MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.
- 09/23/2021
|
Immuron planned Acquisition of R&D Vaccine Company
- MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021.
- 09/23/2021
|
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
|
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
- MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week.
- 01/11/2021
|
Immuron SARS-CoV-2 Research Agreement with Monash University
|
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
|
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
- MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately US$20.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from this offering to fund Immuron’s research and development, preclinical and clinical programs, support marketing initiatives surrounding the Company’s flagship product Travelan and provide ongoing working capital for the Company.The Securities and Exchange Commission declared effective a registration statement on Form F-3 (File No. 333-230762) relating to these securities on April 17, 2019. A final prospectus relating to this offering has been filed with the Securities and Exchange Commission. The offering was made only by means of a prospectus. Electronic copies of the final prospectus relating to the offering may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.This release has been authorised by the directors of Immuron Limited.COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com INVESTOR RELATIONS: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 Dave@redchip.com About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).About Travelan®Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.About Travelers’ diarrheaTravelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.For more information visit: http://www.immuron.comFORWARD-LOOKING STATEMENTS:This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, statements regarding the use of proceeds as well as any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: market and other conditions, risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
- 07/23/2020
|
Introducing Immuron (ASX:IMC), The Stock That Soared 387% In The Last Year
- While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...
- 07/22/2020
|
Immuron's stock pulls back but still nearly doubles after stock offering
- Shares of Immuron Ltd. nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary shares. The offering to "several healthcare-focused institutional investors, which represents about 24% of the ADS outstanding, was priced at $18.75 per ADS. That's below current premarket trading levels, but is 80% above Monday's closing price of $10.41. The stock was up 93% in premarket trading in record territory, but was up as much as 148% earlier. The company had announced earlier that its IMM-124E used to make its gastrointestinal and digestive health immune supplements Travelan and Proectyn demonstrated neutralizing activity against SARS-CoV-2, but that was in "laboratory studies." The stock had run up 63.4% on Monday. It has nearly tripled (up 187%) year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 21.0% and the S&P 500 has gained 0.7%.
- 07/21/2020
|
Immuron Announces $20.0 Million Registered Direct Offering
- MELBOURNE, Australia, July 21, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- 07/21/2020
|
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
- Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studiesImmuron’s technology platform.
- 07/21/2020
|
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
- Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted.
- 07/20/2020
|
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
- Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc. MELBOURNE, Australia, June 19, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the progress made to date on the company’s research collaboration with the Naval Medical Research Center (NMRC) previously announced in October 2019.
- 06/19/2020
|
Price Over Earnings Overview: Immuron
- In the current session, Immuron Inc. (NASDAQ: IMRN) is trading at $10.30, after a 20.06% spike. Over the past month, the stock increased by 412.50%, and in the past year, by 248.01%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 64.47%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Compared to the aggregate P/E ratio of the 0.16 in the Biotechnology industry, Immuron Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/15/2020
|
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Imara Inc (NASDAQ: IMRA) * IMMURON LTD/S ADR (NASDAQ: IMRN)( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) * Inari Medical Inc (NASDAQ: NARI) * Keros Therapeutics Inc (NASDAQ: KROS) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * United Therapeutics Corporation (NASDAQ: UTHR) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) * Applied Molecular Transport Inc (NASDAQ: AMTI) (IPOed Friday) * Ayala Pharmaceuticals Inc (NASDAQ: AYLA)Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.The companies expect the deal to close in the third quarter, and Tetraphase will go private following the consummation.The stock added 14.93% to $2.54 in after-hours trading.Vermillion To Join Russell 3000 Index Women's health company Vermillion, Inc. (NASDAQ: VRML) announced it is set to join the broad-market Russell 3000 Index, effective after the market opens on June 29."We are thrilled to join the Russell 3000, which we believe will attract broader interest in Vermillion from institutional investors and investment funds," said Valerie Palmieri, CEO of Vermillion, Inc.In after-hours trading, the stock added 5.57% to $4.74.Merck's Keytruda Flunks Late-Stage Bladder Cancer Study Merck & Co., Inc. (NYSE: MRK) said the Phase 3 KEYNOTE-361 trial that is evaluating its Keytruda in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet the dual primary endpoints of overall survival and progression-free survival.The company said the monotherapy arm of the study was not formally tested, since superiority was not reached in the combo arm. The safety profile, however, was consistent with previously reported studies.Curis Extends Tuesday's Late-Session Rally Curis, Inc. (NASDAQ: CRIS), which began to gain momentum after 2 p.m. ET Tuesday, is advancing strongly amid a lack of any news release from the company.The stock soared 88.52% to $2.30 in after-hours trading, adding to the nearly 42% jump in regular session.AbbVie To Pay Up to $3.9B For Oncology Partnership With Genmab GENMAB A/S/S ADR (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) Genmab and AbbVie announced a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody product candidates. The companies also agreed for a research collaboration for future differentiated antibody therapeutics for cancer.The agreement provides for AbbVie paying Genmab $750 million in upfront payment with the potential for Genmab to receive up to $3.15 billion in additional development, regulatory and sales milestone payments for all programs, as well as tiered royalties between 22% and 26% on net sales for epcoritamab outside the U.S. and Japan.In pre-market trading, Genmab shares were rising 4.16% to $30.06 and AbbVie shares were little changed with a positive bias.Pfizer Reports Positive Late-Stage Study For Eczema Drug Pfizer Inc. (NYSE: PFE) announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily JAK1 inhibitor, in patients 12 to 18 years of age with moderate to severe atopic dermatitis who were also on background topical therapy. Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated.Fulcrum Plans To Evaluate Pipeline Asset In Phase 3 Trial For COVID-19 Fulcrum Therapeutics Inc (NASDAQ: FULC) said it plans to evaluate losmapimod as a potential treatment for patients with COVID-19.The company said it has submitted an IND application to support initiation of a Phase 3 clinical trial in hospitalized patients in the U.S. following Pre-IND consultation via the Coronavirus Treatment Acceleration ProgramVertex Gets Label Expansion For Its Cystic Fibrosis Treatment In Europe Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said the European Commission has granted approval for the label extension for Kalydeco to include the treatment of children and adolescents with cystic fibrosis, ages 6 months and older and weighing at least 5 kg, who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator gene.Denali Therapeutics Stalls Neurological Drug Study Denali Therapeutics (NASDAQ: DNLI) said it has decided along with its partner Sanofi SA (NASDAQ: SNY) to pause clinical studies with DNL747 and focus efforts on accelerating development of DNL788, which according to the company has superior drug properties and a more rapid path toward proof-of-concept clinical studies in patients in multiple neurological indications.The company attributed the decision to pause the study to emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and challenges to achieving higher doses imposed by molecule-specific toxicity findings with DNL747 in preclinical studies.Denali shares fell 6.85% to $23.95 in after-hours trading.Illumina's COVID Test Issued FDA Emergency Use Authorization Illumina, Inc. (NASDAQ: ILMN) said the FDA issued an Emergency Use Authorization for the Illumina COVIDSeq Test, a high-throughput, sequencing-based in vitro diagnostic workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options available for labs to scale diagnostic testing.Offerings Cardiovascular Systems Inc (NASDAQ: CSII) said it priced its previously announced underwritten public offering of 3.68 million shares at $34 per share. The offering is expected to close on June 12, subject to customary closing conditions.In after-hours trading, the stock fell 9.46% to $34.75.Immunic Inc (NASDAQ: IMUX) said it has commenced a public offering of shares of its common stock. The company said it intends to use the proceeds to fund the ongoing clinical development of its three small molecule products: IMU-838, IMU-935 and IMU-856, and for other general corporate purposes, including to investigate IMU-838, the Company's lead asset, as a potential oral treatment option for COVID-19.The stock fell 6.33% to $11.99 in after-hours trading.CareDx Inc (NASDAQ: CDNA) said it intends to sell up to $100 million of shares of its common stock in an underwritten public offering.. All of the shares will be offered and sold by the company.The stock moved down 1.50% to $32.89 in after-hours trading.See more from Benzinga * The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates * The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage * The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets 0M Bid(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/10/2020
|
Nano-Cap Drugmaker Surges 1,000% as Retail Enthusiasm Spreads
- (Bloomberg) -- Nano-cap Immuron Ltd. saw shares surge more than ten-fold on Tuesday afternoon as euphoria for retail traders took to the biopharmaceutical industry.The Australia-based company, which was valued at roughly $9 million coming into Tuesday’s session, saw its American depository receipts change hands at a record clip as retail investors cheered and Twitter users were left confused. More than 74 million shares were traded Tuesday which compares to a one-year average volume of less than 100 thousand.The biopharmaceutical company disclosed earlier that the Naval Medical Research Center, its partner, requested a regulatory meeting with the U.S. Food and Drug Administration so it could test its drug for the prevention of acute infectious diarrhea. The pair will plan to start a pair of mid-stage trials sometime in the first half of next year if all goes well with regulators.Tuesday’s 850% gain marked the firm’s best single session since going public in 2017 and is an all-time high.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 06/09/2020
|
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA
- The U.S.-listed shares of of Immuron Ltd. skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday, after the Australia-based biopharmaceutical company said its research partner, the Naval Medical Research Center (NMRC) has requested a pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding the treatment being developed for severe campylobactcampylobacteriosis and ETEC infections (E-Coli). The stock was trading at $20.65, or 890.4% above Monday's closing price of $2.10. Trading volume blasted off to 65.5 million shares, compared with the full-day average of about 5,900 shares and nearly 15 times the 4.4 million shares outstanding. "The Australian Importation permit required to ship the vaccines from the NMRC was approved by Biosecurity Australia and the NMRC vaccines were shipped to our contract research partner to commence the project," said Immuron Chief Executive Jerry Kanellos. "The plan is to have the product completed by the end of this year and have it ready for clinical evaluation next year." The stock was down 42.1% year to date as of Monday's close, before Tuesday's rally, while the iShares Nasdaq Biotechnology ETF had gained 10.4% over the same time and the S&P; 500 was up less than 0.1%.
- 06/09/2020
|
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the company’s research collaboration with the Naval Medical Research Center (NMRC) to develop and clinically evaluate a new therapeutic against campylobacter and ETEC (E-Coli). The NMRC recently requested a Pre-IND meeting with the U.S. Food and Drug administration (FDA) regarding its new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and ETEC infections.
- 06/09/2020
|
Immuron Board Relinquish Cash Payment of Fees
- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash payments of Board fees will be suspended and replaced with Immuron stock. As announced to the market on 25 March, 2020 the Board and Executive Management reported that significant cost reductions measures have been implemented to preserve the Company’s cash position. As part of these measures, Immuron’s Board of Directors (‘the Board’) have resolved, for the foreseeable future, to relinquish cash payments of fees and in lieu of same receive common stock in the Company.
- 04/28/2020
|
55 Stocks Moving In Monday's Mid-Day Session
- Gainers
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) shares climbed 93.6% to $12.41 after the company announced a collaboration agreement with the University of Edinburgh to...
- 04/20/2020
|
Immuron North American Travelan Sales Up 95%, Global Sales Up 60%
- Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to $475K.
- 04/20/2020
|
Reviewing IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC)
- IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares IMMURON LTD/S and Intec Pharma’s net margins, return on equity and return […]
- 04/12/2020
|
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated
- 04/07/2020
|
Analyzing Intra-Cellular Therapies (NASDAQ:ITCI) and IMMURON LTD/S (NASDAQ:IMRN)
- Intra-Cellular Therapies (NASDAQ:ITCI) and IMMURON LTD/S (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Volatility and Risk Intra-Cellular Therapies has a beta of 1.91, suggesting that its stock price […]
- 03/31/2020
|
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord Blood Corp (NYSE: CO) * Thermogenesis Holdings Inc (NASDAQ: THMO)(reacted to its fourth-quarter
- 03/25/2020
|
Resignation of CEO & Director and cost cutting amidst COVID-19
- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The keystone of this strategy will be the preservation of capital to allow the Company to weather the current trading conditions pending strengthening of the travel market.
- 03/25/2020
|
Is Immuron (ASX:IMC) In A Good Position To Invest In Growth?
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 03/19/2020
|
Immuron Provides Update on First Half of FY20 Results
- Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from.
- 03/03/2020
|
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
- Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and.
- 02/03/2020
|
North American Travelan® sales up 98% in the first half of FY20
- Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY.
- 01/28/2020
|
Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
- MELBOURNE, Australia, Jan. 08, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- 01/08/2020
|
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
- Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to.
- 11/21/2019
|
Could Immuron Limited's (ASX:IMC) Investor Composition Influence The Stock Price?
- The big shareholder groups in Immuron Limited (ASX:IMC) have power over the company. Generally speaking, as a company...
- 11/13/2019
|
Immuron Receives AUD $0.53M R&D Tax Concession Refund
- MELBOURNE, Australia, Nov. 04, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
- 11/04/2019
|
A Look At Benzinga Pro's Most-Searched Tickers For October 14, 2019
- This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
- 10/14/2019
|
Immuron North American Q1 Sales Up 111% YoY
- Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUDQ1 US Travelan® sales increased by +81% YoY to $232K AUDGlobal Immuron sales.
- 10/14/2019
|
A Look At Benzinga Pro's Most-Searched Tickers For October 3, 2019
- This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Bed Bath & Beyond (NASDAQ: BBBY ) shares were ...
- 10/03/2019
|
A Look At Benzinga Pro's Most-Searched Tickers For October 2, 2019
- This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. TD Ameritrade (NASDAQ: AMTD ) shares were ...
- 10/02/2019
|
Immuron Receives $3.7M In Federal Dollars For Traveler's Diarrhea Preventative Therapy Project
- The Australian biotech said it has reached an agreement with the U.S. Naval Medical Research Center, or NMRC, to collaborate on the manufacturing and evaluation of a new product designed to protect against traveler's diarrhea caused by campylobacter and ETEC pathogens.
- 10/02/2019
|
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter
- NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the Naval Medical Research Center (NMRC), Silver Spring, MD, USA. The focus of this new agreement will be to develop a combined Campylobacter and enterotoxigenic E. coli (ETEC)-specific anti-microbial preventative for clinical evaluation.
- 10/02/2019
|
Should You Be Concerned About Immuron Limited's (ASX:IMC) Historical Volatility?
- Anyone researching Immuron Limited (ASX:IMC) might want to consider the historical volatility of the share price...
- 09/25/2019
|
